BioSpace News Archive

The company announced Monday its shareholders elected Susan Langer, current president of Souffle Therapeutics, to its board of directors, replacing her reputed romantic partner Alex Denner.

The industry, seen as a lucrative target, has been victim of more and more cybersecurity breaches since the start of the COVID-19 pandemic.

Following a May 2023 settlement with Amgen, J&J has also signed an agreement with Teva and Alvotech, allowing their Stelara biosimilar to enter the U.S. no later than February 21, 2025.

The initial public offering on the Nasdaq is a last-ditch effort by the biotech as there is “substantial doubt” as to the company’s “ability to continue as a going concern” without the IPO, according to its SEC filing.

Data from a Phase II trial showed that Adcetris, used in a combination approach, is effective in early-stage classical Hodgkin lymphoma patients.

Valneva’s chikungunya vaccine candidate VLA1553 showed that the shot safely and rapidly induced high rates of seroprotection. Merck earlier in 2023 discontinued its chikungunya program.

Valneva SE, a specialty vaccine company, announces that the Company’s pivotal Phase 3 data for its single-shot chikungunya vaccine candidate, VLA1553, have been published in The Lancet, the world’s leading peer-reviewed medical journal.

Genezen, a gene and cell therapy contract development and manufacturing organization, announced the appointment of Susan D’Costa, Ph.D. as Chief Technology Officer and Nicole O’Brien, Ph.D. as Chief Commercial Officer.

Valo Therapeutics Oy, the developer of novel, adaptable immunotherapies for cancer, announces a collaboration with global contract research organization, Texcell, to investigate immune responses to PeptiCRAd-1 in its Phase 1 clinical study.

Seagen Inc. announced updated efficacy and safety results from Part C of a phase 2 single-arm trial evaluating the antibody-drug conjugate ADCETRIS® in combination with the PD-1 inhibitor nivolumab and standard chemotherapy agents doxorubicin and dacarbazine for the frontline treatment of patients with early-stage classical Hodgkin lymphoma.